| Nitrogen containing heterocycles as anticancer agents: a medicinal chemistry perspective A Kumar, AK Singh, H Singh, V Vijayan, D Kumar, J Naik, S Thareja, ... Pharmaceuticals 16 (2), 299, 2023 | 80 | 2023 |
| Concept of hybrid drugs and recent advancements in anticancer hybrids AK Singh, A Kumar, H Singh, P Sonawane, H Paliwal, S Thareja, ... Pharmaceuticals 15 (9), 1071, 2022 | 67 | 2022 |
| Metal Complexes in cancer treatment: Journey so far A Kumar Singh, A Kumar, H Singh, P Sonawane, P Pathak, M Grishina, ... Chemistry & biodiversity 20 (4), e202300061, 2023 | 25 | 2023 |
| Medicinal chemistry perspective of pyrido [2, 3-d] pyrimidines as anticancer agents A Kumar, KK Bhagat, AK Singh, H Singh, T Angre, A Verma, H Khalilullah, ... RSC advances 13 (10), 6872-6908, 2023 | 19 | 2023 |
| Gaussian field-based 3D-QSAR and molecular simulation studies to design potent pyrimidine–sulfonamide hybrids as selective BRAF V600E inhibitors AK Singh, J Novak, A Kumar, H Singh, S Thareja, P Pathak, M Grishina, ... RSC advances 12 (46), 30181-30200, 2022 | 18 | 2022 |
| Regulation of thymidylate synthase: an approach to overcome 5-FU resistance in colorectal cancer A Kumar, AK Singh, H Singh, S Thareja, P Kumar Medical Oncology 40 (1), 3, 2022 | 15 | 2022 |
| Role of collagen regulators in cancer treatment: A comprehensive review T Angre, A Kumar, AK Singh, S Thareja, P Kumar Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal …, 2022 | 14 | 2022 |
| Insights into the mechanisms of diabetic wounds: pathophysiology, molecular targets, and treatment strategies through conventional and alternative therapies JP Yadav, AK Singh, M Grishina, P Pathak, A Verma, V Kumar, P Kumar, ... Inflammopharmacology 32 (1), 149-228, 2024 | 9 | 2024 |
| Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022 AK Singh, P Sonawane, A Kumar, H Singh, V Naumovich, P Pathak, ... ACS omega 8 (31), 27819-27844, 2023 | 9 | 2023 |
| A review of pyridine and pyrimidine derivatives as anti-MRSA agents A Kumar, AK Singh, S Thareja, P Kumar Anti-Infective Agents 21 (2), 18-40, 2023 | 8 | 2023 |
| Current insights into the role of BRAF inhibitors in treatment of melanoma AK Singh, A Kumar, S Thareja, P Kumar Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal …, 2023 | 8 | 2023 |
| Cucumis melo var. agrestis Naudin as a potent antidiabetic: Investigation via experimental methods JP Yadav, AK Singh, M Grishina, P Pathak, DK Patel Phytomedicine Plus 2 (4), 100340, 2022 | 8 | 2022 |
| Bacteriophages concept and applications: A review on phage therapy R Sahu, AK Singh, A Kumar, K Singh, P Kumar Current Pharmaceutical Biotechnology 24 (10), 1245-1264, 2023 | 7 | 2023 |
| Current insights and molecular docking studies of the drugs under clinical trial as RdRp inhibitors in COVID-19 treatment I Pauly, A Kumar Singh, A Kumar, Y Singh, S Thareja, MA Kamal, ... Current Pharmaceutical Design 28 (46), 3677-3705, 2022 | 7 | 2022 |
| MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives T Ram, AK Singh, A Kumar, H Singh, P Pathak, M Grishina, H Khalilullah, ... RSC Medicinal Chemistry, 2023 | 6 | 2023 |
| A comprehensive review on additive manufacturing of medical devices. Prog Addit Manuf 6: 517–553 LRR da Silva, WF Sales, F Campos, JAG de Sousa, R Davis, A Singh, ... | 5 | 2021 |
| An insight to heat shock protein 90: A remedy for multiple problems M Yadav, AK Singh, A Kumar, S Thareja, P Kumar Current Pharmaceutical Design 28 (32), 2664-2676, 2022 | 3 | 2022 |
| Virtual screening, structure based pharmacophore mapping, and molecular simulation studies of pyrido [2, 3-d] pyrimidines as selective thymidylate synthase inhibitors A Kumar, J Novak, AK Singh, H Singh, S Thareja, P Pathak, M Grishina, ... Journal of Biomolecular Structure and Dynamics 41 (23), 14197-14211, 2023 | 2 | 2023 |
| In Silico Studies of Indole Derivatives as Antibacterial Agents M Shah, A Kumar, AK Singh, H Singh, B Narasimhan, P Kumar Journal of Pharmacopuncture 26 (2), 147, 2023 | 2 | 2023 |
| Description and in silico ADME studies of US-FDA approved drugs or drugs under clinical trial which violate the Lipinski’s rule of 5 L Niyatha, AK Singh, A Kumar, H Singh, JP Yadav, K Singh, P Kumar Letters in Drug Design & Discovery, 2023 | 2* | 2023 |
Amita VermaSam Higginbottom University of Agriculture, Technology and Sciences, Allahabad在 shiats.edu.in 的电子邮件经过验证
